Search Results
Your search for Wendy LaGrego matches 76 pages
Showing 1 - 50Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer (NSCLC) whose disease had...
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
According to results from the phase III SAFFRON trial, the combination of osimertinib and savolitinib significantly improved progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) with MET...
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
A hypofractionated radiotherapy regimen was noninferior to conventional radiotherapy for locoregional control among patients with high-risk breast cancer undergoing postmastectomy radiotherapy with internal mammary node irradiation, according to findings from the phase III HypoMast-IMNI trial...
Phase III VOLGA Trial: Durvalumab/Tremelimumab/Enfortumab Vedotin Improves Outcomes in Bladder Cancer
In the phase III VOLGA trial, researchers evaluated the use of perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy....
Financial Navigation Program May Help Reduce Cancer-Related Financial Hardship
A financial navigation intervention was associated with significant reductions in financial toxicity among patients with cancer across rural and nonrural oncology practices, according to findings from the Lessening the Impact of Financial Toxicity (LIFT) trial reported by Wheeler et al in the...
F-SHARP Trial Evaluates Focal Salvage Brachytherapy and Genomic Risk Stratification in Recurrent Prostate Cancer
According to findings from the phase I/II F-SHARP trial reported by Solanki et al in the Journal of Clinical Oncology, dose-escalated focal salvage high–dose rate brachytherapy demonstrated favorable disease control with low rates of severe toxicity in patients with locally recurrent prostate...
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Expert histopathologic evaluation followed by molecular analyses when necessary provided a definitive diagnosis in more than 97% of patients with ambiguous primary cutaneous melanocytic tumors, according to findings from a prospective cohort study reported by Ebbelaar et al in the Journal of...
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al...
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the...
Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer
The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific...
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved...
Facilitated Cascade Genetic Testing Improves Uptake Among Relatives of BRCA1/2 Variant Carriers
According to findings from a randomized controlled trial reported by Wilke et al in the Journal of Clinical Oncology, a clinician-facilitated approach to cascade genetic testing significantly increased genetic testing uptake among first-degree relatives of individuals with BRCA1 or BRCA2 pathogenic ...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
Study Identifies Insurance and Cost Barriers to Oral Therapies for Blood Cancers
A nationwide study of patients with blood cancers found that most prescriptions for specialty oral anticancer medications were initially rejected by insurers, and many patients did not fill their prescriptions even after receiving approval. The findings, reported by Doshi et al in the Journal of...
Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer
A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node...
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
According to findings from a phase III trial reported by Weinberg et al in the Journal of Clinical Oncology, intraoperative tile-based radiation therapy with cesium-131 significantly improved surgical bed control compared with postoperative stereotactic radiation therapy in patients undergoing...
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence?
Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age...
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers...
Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment
Mindfulness-based cancer recovery and Tai Chi/Qigong were associated with improvements in fatigue and pain interference among distressed individuals who had completed cancer treatment, with Tai Chi/Qigong also improving sleep quality, according to findings from the Mindfulness and Tai Chi for...
Phase III Trial Compares HER2-Directed Antibody-Drug Conjugates in Advanced Breast Cancer
According to findings from a phase III randomized trial reported by Zhang et al in the Journal of Clinical Oncology, the novel HER2-directed antibody-drug conjugate trastuzumab botidotin significantly prolonged progression-free survival compared with ado-trastuzumab emtansine (T-DM1) in patients...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma
The 5-year follow-up of the phase II OPTIMUM/MUKnine trial found sustained improvements in progression-free and overall survival with an intensive, risk-adapted treatment strategy for patients with newly diagnosed high-risk multiple myeloma. The findings, reported by Kaiser et al in The Lancet...
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
Early-onset colorectal cancer appears to share much of its genomic landscape with average-onset colorectal cancer, although certain molecular alterations may be enriched among younger patients, according to findings reported by Shin et al in JCO Precision Oncology. The investigators examined...
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
According to the results of a retrospective analysis reported by Jeong et al in JCO Precision Oncology, early molecular response assessed using circulating tumor DNA (ctDNA) was associated with radiographic response and longer time to progression among patients with recurrent high-grade serous...
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
A refined dynamic prognostic model incorporating longitudinal measurable residual disease (MRD) assessments may improve prediction of progression-free survival and overall survival in patients with chronic lymphocytic leukemia (CLL) receiving limited-duration therapy. The findings, reported by...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence
According to interim results of the phase III SHARE trial reported by Song et al in the Journal of Clinical Oncology, hypofractionated salvage radiotherapy produced similar 4-year oncologic outcomes to conventional radiotherapy among patients with biochemical recurrence after radical prostatectomy, ...
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
The combination of the epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin and the PD-1 inhibitor pucotenlimab demonstrated antitumor activity in patients with recurrent or metastatic nasopharyngeal carcinoma previously treated with platinum-based...
Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors
According to findings from the prospective multicenter LAANTERN study reported by Leuthardt et al in the Journal of Clinical Oncology, laser interstitial thermal therapy (LITT) may offer a minimally invasive cytoreductive option for selected patients with primary and metastatic brain tumors, with...
Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy
Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating...
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
Flight attendants and pilots had the highest and second-highest risk-adjusted percentages of deaths from radiation-related cancers, respectively, among more than 500 occupations in the United States, according to the results of a population-based analysis reported by Patel et al in a research...
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
According to the results of a phase II study reported by Lynch et al in the Journal of Clinical Oncology, a chemotherapy-free approach using subcutaneous single-agent mosunetuzumab, or, for patients without an initial complete response, mosunetuzumab followed by polatuzumab vedotin plus...
Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer
Tumor genomic alterations and transcriptomic subtypes may provide prognostic information in patients with resected pancreatic ductal adenocarcinoma (PDAC), but most did not predict differential benefit from adjuvant modified FOLFIRINOX (mFOLFIRINOX) vs gemcitabine, according to an analysis of the...
QOL Impact of Postmastectomy Chest Wall Radiotherapy: 5-Year Follow-up
In the 5-year quality-of-life (QOL) analysis of the phase III SUPREMO trial published in The Lancet Oncology, Velikova et al found that women with intermediate-risk breast cancer who received postmastectomy chest wall radiotherapy experienced modestly worse local chest wall symptoms at 5 years, but ...
Darolutamide Plus Goserelin in AR-Positive Salivary Gland Carcinoma
Patients with androgen receptor (AR)–positive salivary gland carcinoma treated with darolutamide plus goserelin experienced greater antitumor activity than those treated with darolutamide alone in the Japanese phase II DISCOVARY trial, while both approaches demonstrated manageable safety profiles...
Does ctDNA-Guided Surveillance After Curative-Intent Surgery Benefit Outcomes in Cases of Recurrent Colorectal Cancer?
Dynamic surveillance using circulating tumor DNA (ctDNA) methylation testing after curative-intent surgery significantly increased the proportion of patients with recurrent nonmetastatic colorectal cancer who were able to undergo curative-intent treatment, according to results of the phase III FIND ...
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
In a phase Ib study published in the Journal of Clinical Oncology, Zhao et al found that the first-in-class bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren, BL-B01D1), which targets EGFR and HER3, demonstrated antitumor activity in patients with relapsed extensive-stage...
AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
A histology-based artificial intelligence (AI) biomarker may help personalize adjuvant chemotherapy selection for patients with resected pancreatic ductal adenocarcinoma, according to the results of a study by Beaufils et al. The investigators developed and validated a deep learning model that...
Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer
In a multicenter Chinese randomized phase III trial published in the Journal of Clinical Oncology, Wang et al found that an intensified total neoadjuvant therapy approach integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy improved disease-free survival ...
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC
In a phase II study published in the Journal of Clinical Oncology, Rimner et al found that concurrent and consolidative durvalumab administered with definitive radiation therapy, without chemotherapy, demonstrated encouraging efficacy in patients with inoperable locally advanced non–small cell lung ...
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
According to the results of a phase I study reported by Srour et al in the Journal of Clinical Oncology, the investigational allogeneic CD70-targeted chimeric antigen receptor (CAR) T-cell therapy ALLO-316 showed encouraging clinical activity with a manageable safety profile in heavily pretreated...
Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress
In a recent study reported in the Journal of Clinical Oncology, Rognvaldsson et al found that population-based screening for monoclonal gammopathy of undetermined significance (MGUS) led to substantially earlier detection of smoldering multiple myeloma and earlier diagnosis of active multiple...
Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS
Patients with previously untreated higher-risk myelodysplastic syndromes (MDS) did not experience improved outcomes with the addition of the anti-CD47 antibody magrolimab to azacitidine compared with azacitidine alone, according to the results of the phase III ENHANCE trial reported by Sallman et...
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than...
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
Oral nicotinamide (vitamin B3) may provide a cost-effective strategy for preventing keratinocyte carcinoma (KC) in persons at high risk, according to a study published in JAMA Dermatology. Led by David Perez, BA, the study was designed to determine whether the clinical benefits previously observed...
Expert Dermatologists Outperform AI Foundation Models in Real-World Skin Cancer Diagnosis
According to a diagnostic study reported in JAMA Dermatology by Anriot et al, a modern artificial intelligence (AI) foundation model outperformed less experienced clinicians but did not match the diagnostic performance of expert dermatologists when tested under realistic clinical conditions. The...
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
In the long-term follow-up to a phase II study published in The New England Journal of Medicine, Ruella et al found that a single infusion of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 (now called tisagenlecleucel) produced decade-long remissions in a subset of patients ...
